Biotech News

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Ardelyx (ARDX)ArdelyxClinical readout

Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life

Related news

Ardelyx

NHE3 Inhibition Platform Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract. Its approach changes intestinal sodium transport and can affect bowel function and phosphate absorption. IBSRELA and XPHOZAH IBSRELA is approved for irritable bowel syndrome with...

Recent company news

Stock data

Close
3.06 USD
Market cap
1.36B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States